Last reviewed · How we verify

Clofarabine, ara-C — Competitive Intelligence Brief

Clofarabine, ara-C (Clofarabine, ara-C) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog and cytosine analog. Area: Oncology.

phase 2 Nucleoside analog and cytosine analog Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Clofarabine, ara-C (Clofarabine, ara-C) — Hannover Medical School. Clofarabine is a nucleoside analog that interferes with DNA synthesis, while ara-C is a cytosine analog that also interferes with DNA synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Clofarabine, ara-C TARGET Clofarabine, ara-C Hannover Medical School phase 2 Nucleoside analog and cytosine analog

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog and cytosine analog class)

  1. Hannover Medical School · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clofarabine, ara-C — Competitive Intelligence Brief. https://druglandscape.com/ci/clofarabine-ara-c. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing